- Home
- AUTL vs PHAR Comparison
AUTL vs PHAR Comparison
Compare AUTL & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- PHAR
- Stock Information
- Founded
- AUTL 2014
- PHAR 1988
- Country
- AUTL United Kingdom
- PHAR Netherlands
- Employees
- AUTL N/A
- PHAR N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- PHAR Health Care
- Exchange
- AUTL Nasdaq
- PHAR Nasdaq
- Market Cap
- AUTL 590.8M
- PHAR 618.3M
- IPO Year
- AUTL 2018
- PHAR N/A
- Fundamental
- Price
- AUTL $2.17
- PHAR $8.20
- Analyst Decision
- AUTL Strong Buy
- PHAR Strong Buy
- Analyst Count
- AUTL 3
- PHAR 3
- Target Price
- AUTL $10.20
- PHAR $27.00
- AVG Volume (30 Days)
- AUTL 1.1M
- PHAR 5.6K
- Earning Date
- AUTL 03-13-2025
- PHAR 03-13-2025
- Dividend Yield
- AUTL N/A
- PHAR N/A
- EPS Growth
- AUTL N/A
- PHAR N/A
- EPS
- AUTL N/A
- PHAR N/A
- Revenue
- AUTL $10,091,000.00
- PHAR $285,745,000.00
- Revenue This Year
- AUTL $851.83
- PHAR $20.08
- Revenue Next Year
- AUTL $224.65
- PHAR $9.22
- P/E Ratio
- AUTL N/A
- PHAR N/A
- Revenue Growth
- AUTL 82.71
- PHAR 30.64
- 52 Week Low
- AUTL $2.07
- PHAR $6.65
- 52 Week High
- AUTL $7.37
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- AUTL 41.81
- PHAR 36.29
- Support Level
- AUTL $2.11
- PHAR $8.49
- Resistance Level
- AUTL $2.26
- PHAR $9.35
- Average True Range (ATR)
- AUTL 0.12
- PHAR 0.55
- MACD
- AUTL 0.01
- PHAR -0.17
- Stochastic Oscillator
- AUTL 27.78
- PHAR 12.14
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.